Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi®) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells.
Maria FaviaCrescenzio GalloLorenzo GuerraDomenica De VenutoAnna DianaAngela Maria PolizziPasqualina MontemurroMaria Addolorata MariggiòGiuseppina LeonettiAntonio MancaValeria CasavolaMassimo ConesePublished in: International journal of molecular sciences (2020)
The treatment of cystic fibrosis (CF) patients homozygous for the F508del mutation with Orkambi®, a combination of a corrector (lumacaftor) and a potentiator (ivacaftor) of the mutated CFTR protein, resulted in some amelioration of the respiratory function. However, a great variability in the clinical response was also observed. The aim of this study was to evaluate the response to Orkambi® in a small cohort of F508del/F508del patients (n = 14) in terms of clinical and laboratory parameters, including ex vivo CFTR activity in mononuclear cells (MNCs), during a 12-month treatment. Patients responded with an increase in percent predicted forced expiratory volume in 1 s (FEV1%) and body mass index (BMI) as well as with a decrease in white blood cell (WBC) total counts and serum C-reactive protein (CRP) levels, although not significantly. Sweat chloride and CFTR-dependent chloride efflux were found to decrease and increase, respectively, as compared with pre-therapy values. CFTR and BMI showed a statistically significant correlation during Orkambi® treatment. Clustering analysis showed that CFTR, BMI, sweat chloride, FEV1%, and WBC were strongly associated. These data support the notion that CFTR-dependent chloride efflux in MNCs should be investigated as a sensitive outcome measure of Orkambi® treatment in CF patients.
Keyphrases
- cystic fibrosis
- end stage renal disease
- body mass index
- pseudomonas aeruginosa
- newly diagnosed
- ejection fraction
- chronic kidney disease
- lung function
- prognostic factors
- intensive care unit
- stem cells
- peripheral blood
- mesenchymal stem cells
- replacement therapy
- cell death
- combination therapy
- chronic obstructive pulmonary disease
- amino acid